Driving CAR T-cells forward

Nature Reviews Clinical Oncology

Volumn 13, Issue 6, 2016, Pages 370-383

  Jackson, Hollie J ^a   Rafiq, Sarwish ^a   Brentjens, Renier J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUDARABINE; GLYPICAN 3; HYPERTENSIVE AGENT; INTERLEUKIN 2; IPILIMUMAB; MESOTHELIN; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR; NERVE CELL ADHESION MOLECULE L1; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SEPRASE; STEROID; TOCILIZUMAB; TRASTUZUMAB; VASCULOTROPIN RECEPTOR 2; CYTOKINE; TUMOR ANTIGEN; TUMOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ACUTE RESPIRATORY FAILURE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTIFICIAL VENTILATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COLORECTAL CANCER; CYTOKINE RELEASE SYNDROME; DRUG FATALITY; DRUG MEGADOSE; FEVER; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA REMISSION; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG CANCER; MANTLE CELL LYMPHOMA; MELANOMA; METASTASIS; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; NEUROBLASTOMA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATIENT SAFETY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SARCOMA; STOMACH CANCER; T LYMPHOCYTE; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR VASCULARIZATION; ADOPTIVE IMMUNOTHERAPY; BIOLOGICAL THERAPY; CHIMERA; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS; PROCEDURES; TREATMENT OUTCOME;

ANTIGENS, CD19; ANTIGENS, NEOPLASM; CELL- AND TISSUE-BASED THERAPY; CHIMERA; CYTOKINES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; NEOPLASMS; RNA, MESSENGER; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84961390496     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.36     Document Type: Review

References (164)

1. Brentjens R. J., et al. CD19 targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra138 (2013
2. Lee D. W., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517-528 (2015
3. Maude S. L., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014
4. Jensen M. C., et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19 specific chimeric antigen receptor redirected T cells in humans. Biol. Blood Marrow Transplant. 16, 1245-1256 (2010
5. Lamers C. H., et al. Treatment of metastatic renal cell carcinoma with autologous T lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20-e22 (2006
6. Till B. G., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20 specific T cells. Blood 112, 2261-2271 (2008
7. Savoldo B., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822-1826 (2011
8. Scholler J., et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132ra153 (2012
9. Lee D. W., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517-528 (2014
10. Carpenito C., et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106, 3360-3365 (2009
11. Zhong X. S., Matsushita M., Plotkin J., Riviere I., & Sadelain M. Chimeric antigen receptors combining 4 1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18, 413-420 (2010
12. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01853631 (2015
13. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01044069 (2016
14. Park J. H., et al. Efficacy and safety of CD19 targeted 19 28z CAR modified T cells in adult patients with relapsed or refractory B ALL [abstract]. J. Clin. Oncol. 33 (Suppl.), 7010 (2015
15. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01626495 (2016
16. Grupp S. A., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013
17. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01593696 (2015
18. US National Library of Science ClinicalTrials.gov [online],https://clinicaltrials.gov/ct2/show/NCT01865617 (2015
19. Sommermeyer D., et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30, 492-500 (2015
20. Turtle C. J., et al. Immunotherapy with CD19 specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition [abstract]. J. Clin. Oncol. 33 (Suppl.), 3006 (2015
21. Brentjens R. J., et al. Safety and persistence of adoptively transferred autologous CD19 targeted T cells in patients with relapsed or chemotherapy refractory B cell leukemias. Blood 118, 4817-4828 (2011
22. Kochenderfer J. N., et al. B cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720 (2012
23. Porter D. L., et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified t cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. Presented at the 55th ASH Annual Meeting and Exposition (2014
24. Porter D. L., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015
25. Kochenderfer J. N., et al. Anti CD19 CAR T cells administered after low-dose chemotherapy can induce remissions of chemotherapy-refractory diffuse large B cell lymphoma. Blood 124, 550 (2014
26. Schuster S. J., et al. Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas [abstract]. Blood 124 (Suppl.), 3087 (2014
27. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01840566 (2015
28. Sauter C. S., et al. Phase I trial of 19 28z chimeric antigen receptor modified T cells (19 28z CAR T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B cell non-Hodgkin lymphoma (B NHL) [abstract]. J. Clin. Oncol. 33 (Suppl.), 8515 (2015
29. Davila M. L., et al. Efficacy and toxicity management of 19 28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra225 (2014
30. Porter D. L., Levine B. L., Kalos M., Bagg A., & June C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011
31. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02135406 (2015
32. Garfall A. L., et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N. Engl. J. Med. 373, 1040-1047 (2015
33. Sotillo E., et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART 19 immunotherapy. Cancer Discov. 5, 1282-1295 (2015
34. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02315612 (2015
35. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00621452 (2014
36. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02194374 (2015
37. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00881920 (2016
38. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02215967 (2015
39. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01886976 (2016
40. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01864902 (2016
41. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02159495 (2016
42. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01716364 (2012
43. Nitschke L. CD22 and Siglec G: B cell inhibitory receptors with distinct functions. Immunol. Rev. 230, 128-143 (2009
44. Dotti G., Gottschalk S., Savoldo B., & Brenner M. K. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 257, 107-126 (2014
45. Haso W., et al. Anti CD22 chimeric antigen receptors targeting B cell precursor acute lymphoblastic leukemia. Blood 121, 1165-1174 (2013
46. Till B. G., et al. CD20 specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4 1BB domains: pilot clinical trial results. Blood 119, 3940-3950 (2012
47. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01735604 (2015
48. Wang Y., et al. Effective response and delayed toxicities of refractory advanced diffuse large B cell lymphoma treated by CD20 directed chimeric antigen receptor-modified T cells. Clin. Immunol. 155, 160-175 (2014
49. Zhang S., et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am. J. Pathol. 181, 1903-1910 (2012
50. Al Shawi R., Ashton S. V., Underwood C., & Simons J. P. Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development. Dev. Genes Evol. 211, 161-171 (2001
51. Hudecek M., et al. The B cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1 specific chimeric antigen receptor. Blood 116, 4532-4541 (2010
52. Vera J., et al. T lymphocytes redirected against the ? light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108, 3890-3897 (2006
53. Deniger D. C., et al. Sleeping Beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) into diverse memory T cell populations. PLoS ONE 10, e0128151 (2015
54. Ellis T. M., Simms P. E., Slivnick D. J., Jack H. M., & Fisher R. I. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J. Immunol. 151, 2380-2389 (1993
55. Hombach A., et al. An anti CD30 chimeric receptor that mediates CD3 æ-independent T cell activation against Hodgkin?s lymphoma cells in the presence of soluble CD30. Cancer Res. 58, 1116-1119 (1998
56. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01316146 (2016
57. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02259556 (2016
58. Zhang H., et al. Differential expression of syndecan 1 mediates cationic nanoparticle toxicity in undifferentiated versus differentiated normal human bronchial epithelial cells. ACS Nano 5, 2756-2769 (2011
59. Guo B., et al. CD138 directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J. Cell. Immunother. http://dx.doi.org/10.1016/j.jocit.2014.11.001 (2015
60. Carpenter R. O., et al. B cell maturation antigen is a promising target for adoptive T cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048-2060 (2013
61. Feldman E., et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti CD33 monoclonal antibody HuM195. Leukemia 17, 314-318 (2003
62. Roberts A. W., et al. A phase I study of anti CD123 monoclonal antibody (mAb) CSL360 targeting leukemia stem cells (LSC) in AML [abstract]. J. Clin. Oncol. 28 (Suppl.), e13012 (2010
63. Mardiros A., et al. T cells expressing CD123 specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 122, 3138-3148 (2013
64. Shi J., et al. Identification of CD123+ myeloid dendritic cells as an early-stage immature subset with strong tumoristatic potential. Cancer Lett. 270, 19-29 (2008
65. Tettamanti S., et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123 specific chimeric antigen receptor. Br. J. Haematol. 161, 389-401 (2013
66. Sievers E. L., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33 positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19, 3244-3254 (2001
67. Hoyer J. D., Grogg K. L., Hanson C. A., Gamez J. D., & Dogan A. CD33 detection by immunohistochemistry in paraffin-embedded tissues: a new antibody shows excellent specificity and sensitivity for cells of myelomonocytic lineage. Am. J. Clin. Pathol. 129, 316-323 (2008
68. Wang Q. S., et al. Treatment of CD33 directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol. Ther. 23, 184-191 (2015
69. Kobayashi K., et al. Lewis blood group-related antigen expression in normal gastric epithelium, intestinal metaplasia, gastric adenoma, and gastric carcinoma. Am. J. Gastroenterol. 88, 919-924 (1993
70. Peinert S., et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther. 17, 678-686 (2010
71. Schuessler M. H., et al. Blood group and blood-group-related antigens in normal pancreas and pancreas cancer: enhanced expression of precursor type 1, Tn and sialyl Tn in pancreas cancer. Int. J. Cancer 47, 180-187 (1991
72. Ritchie D. S., et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol. Ther. 21, 2122-2129 (2013
73. Chang S. S. Overview of prostate-specific membrane antigen. Rev. Urol. 6, S13-S18 (2004
74. Haffner M. C., et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum. Pathol. 40, 1754-1761 (2009
75. Maher J., Brentjens R. J., Gunset G., Riviere I., & Sadelain M. Human T lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat. Biotechnol. 20, 70-75 (2002
76. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01140373 (2015
77. Slovin S. F., et al. Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CAR+ T cells. J. Clin. Oncol. 30, TPS4700 (2012
78. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00664196 (2014
79. Junghans R. P., et al. Abstract C13: phase I trial of anti-PSMA designer T cells in advanced prostate cancer. Cancer Res. 72, C13 (2012
80. Hassan R., & Ho M. Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 44, 46-53 (2008
81. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01355965 (2015
82. Beatty G. L., et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2, 112-120 (2014
83. Maus M. V., et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1, 26-31 (2013
84. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02159716 (2016
85. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02414269 (2015
86. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01583686 (2015
87. Mathew S., et al. The gene for fibroblast activation protein α (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. Genomics 25, 335-337 (1995
88. Petrausch U., et al. Re directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME 1). BMC Cancer 12, 615 (2012
89. Schuberth P. C., et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re directed T cells. J. Transl. Med. 11, 187 (2013
90. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01722149 (2016
91. Arteaga C. L. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7 (Suppl. 4), 31-39 (2002
92. Feldkamp M. M., Lala P., Lau N., Roncari L., & Guha A. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45, 1442-1453 (1999
93. Thomas M. Cetuximab: adverse event profile and recommendations for toxicity management. Clin. J. Oncol. Nurs. 9, 332-338 (2005
94. Johnson L. A., et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci. Transl. Med. 7, 275ra222 (2015
95. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02209376 (2016
96. Morgan R. A., et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum. Gene Ther. 23, 1043-1053 (2012
97. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01454596 (2016
98. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02331693 (2015
99. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 9, 67-81 (1999
100. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02416466 (2015
101. Parkhurst M. R., et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620-626 (2011
102. Katz S. C., et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T cell therapy for CEA+ liver metastases. Clin. Cancer Res. 21, 3149-3159 (2015
103. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02349724 (2015
104. Huszar M., et al. Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum. Pathol. 37, 1000-1008 (2006
105. Meli M. L., et al. Anti-neuroblastoma antibody chCE7 binds to an isoform of L1 CAM present in renal carcinoma cells. Int. J. Cancer 83, 401-408 (1999
106. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02311621 (2014
107. Hong H., et al. Diverse solid tumors expressing a restricted epitope of L1 CAM can be targeted by chimeric antigen receptor redirected T lymphocytes. J. Immunother. 37, 93-104 (2014
108. Suzuki M., & Cheung N. K. Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin. Ther. Targets 19, 349-362 (2015
109. Zhang S., et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer 73, 42-49 (1997
110. Louis C. U., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050-6056 (2011
111. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00085930 (2015
112. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02107963 (2016
113. Gargett T., & Brown M. P. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. Cytotherapy 17, 487-495 (2015
114. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01822652 (2015
115. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01953900 (2015
116. Baumhoer D., et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am. J. Clin. Pathol. 129, 899-906 (2008
117. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02395250 (2015
118. Press M. F., Cordon-Cardo C., & Slamon D. J. Expression of the HER 2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5, 953-962 (1990
119. Slamon D. J., et al. Studies of the HER 2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989
120. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00924287 (2015
121. Morgan R. A., et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843-851 (2010
122. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00902044 (2015
123. Ahmed N., et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2 positive sarcoma. J. Clin. Oncol. 33, 1688-1696 (2015
124. Ahmed N., et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol. Ther. 17, 1779-1787 (2009
125. Zhao Y., et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183, 5563-5574 (2009
126. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02442297 (2016
127. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01109095 (2016
128. Debinski W., Gibo D. M., Hulet S. W., Connor J. R., & Gillespie G. Y. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin. Cancer Res. 5, 985-990 (1999
129. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00730613 (2011
130. Brown C. E., et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin. Cancer Res. 21, 4062-4072 (2015
131. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02208362 (2015
132. Chinnasamy D., et al. Local delivery of interleukin 12 using T cells targeting VEGF receptor 2 eradicates multiple vascularized tumors in mice. Clin. Cancer Res. 18, 1672-1683 (2012
133. Chmielewski M., Kopecky C., Hombach A. A., & Abken H. IL 12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71, 5697-5706 (2011
134. Kerkar S. P., et al. IL 12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746-4757 (2011
135. Pegram H. J., et al. Tumor-targeted T cells modified to secrete IL 12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133-4141 (2012
136. Zhang L., et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin 12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278-2288 (2015
137. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02498912 (2015
138. Chekmasova A. A., et al. Successful eradication of established peritoneal ovarian tumors in SCID-beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin. Cancer Res. 16, 3594-3606 (2010
139. Koneru M., O'Cearbhaill R., Pendharkar S., Spriggs D. R., & Brentjens R. J. A phase I clinical trial of adoptive T cell therapy using IL 12 secreting MUC 16ecto directed chimeric antigen receptors for recurrent ovarian cancer. J. Transl. Med. 13, 102 (2015
140. Yin B. W., & Lloyd K. O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem. 276, 27371-27375 (2001
141. Wilkie S., et al. Selective expansion of chimeric antigen receptor-targeted T cells with potent effector function using interleukin 4. J. Biol. Chem. 285, 25538-25544 (2010
142. Davies D. M., et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol. Med. 18, 565-576 (2012
143. van Schalkwyk M. C., et al. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T cells in locally advanced or recurrent head and neck cancer. Hum. Gene Ther. Clin. Dev. 24, 134-142 (2013
144. Zhang J., Basher F., & Wu J. D. NKG2D ligands in tumor immunity: two sides of a coin. Front. Immunol. 6, 97 (2015
145. Spear P., Barber A., Rynda-Apple A., & Sentman C. L. NKG2D CAR T cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol. Cell Biol. 91, 435-440 (2013
146. Sentman C. L., & Meehan K. R. NKG2D CARs as cell therapy for cancer. Cancer J. 20, 156-159 (2014
147. Zhang T., Barber A., & Sentman C. L. Chimeric NKG2D modified T cells inhibit systemic T cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res. 67, 11029-11036 (2007
148. US National Library of Science ClinicalTrials.gov [online], https://www.clinicaltrials.gov/ct2/show/NCT02203825 (2016
149. Rizvi N. A., et al. Mutational landscape determines sensitivity to PD 1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015
150. Robert C., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532 (2015
151. Van Allen E. M., et al. Genomic correlates of response to CTLA 4 blockade in metastatic melanoma. Science 350, 207-211 (2015
152. Choudhury N., & Nakamura Y. The importance of immunopharmacogenomics in cancer treatment: patient selection and monitoring for immune checkpoint antibodies. Cancer Sci 107, 107-115 (2015
153. John L. B., et al. Anti PD 1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636-5646 (2013
154. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00586391 (2015
155. Kershaw M. H., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115 (2006
156. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02465983 (2016
157. Chen J. C., Chang Y. W., Hong C. C., Yu Y. H., & Su J. L. The role of the VEGF C/VEGFRs axis in tumor progression and therapy. Int. J. Mol. Sci. 14, 88-107 (2012
158. Fukumura D., et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715-725 (1998
159. Chinnasamy D., et al. Gene therapy using genetically modified lymphocytes targeting VEGFR 2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Invest. 120, 3953-3968 (2010
160. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01218867 (2015
161. Kochenderfer J. N., et al. Chemotherapy-refractory diffuse large B cell lymphoma and indolent B cell malignancies can be effectively treated with autologous T cells expressing an anti CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540-549 (2015
162. Di Stasi A., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683 (2011
163. Wang X., et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255-1263 (2011
164. US National Library of Science ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01818323 (2015